Clinical Trial

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

Name: A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer — clinical trial record (NCT07691489)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low levels of HER2 and that has gotten worse after receiving standard treatment.

Trial Details

NCT Number	NCT07691489
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: AstraZeneca, Eli Lilly and Company, National Institutes of Health (NIH)
Conditions	Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Enrollment	27 participants
Start Date	2026-08
Primary Completion	2029-06 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-09